2 tracked superinvestors hold GSK PLC (GSK), worth $2.8B combined, led by Team. Smart money is holding GSK as of the latest 13F filings.
Current price
$49.89
+30.5%
1Y
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and…
Market cap
$103.8B
P/E
13.44
Div yield
3.7%
Revenue YoY
4.1%
Analyst target
$52
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
2
tracked 13F / N-PORT funds
Combined value
$2.8B
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
0
1 buying · 1 selling
Smart money is holding GSK steady this quarter — buys and sells are balanced. 1 opened a brand-new position.
GSK PLC (GSK) appears mainly in diversified and quant books here (2 funds, $2.8B combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to Team at 1.6% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
This quarter 1 fund opened a brand-new position (PRIMECAP team), with 0 adding and 1 trimming — a net accumulation signal.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Trimmed | 1.6% | $1.9B | |
| New buy | 1% | $953M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own GSK?
2 tracked funds hold GSK PLC (GSK), the largest being Team (Dodge & Cox Stock) at 1.6% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling GSK?
In the most recent 13F quarter, 1 tracked fund added or opened GSK and 1 trimmed it, including 1 brand-new position.
How much GSK do tracked funds hold?
Combined disclosed long exposure to GSK across tracked superinvestors is $2.8B as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.